Waardenburg Syndrome — accounting for 2-5% of all congenital deafness worldwide, where the clinical presentation ranges from subtle pigmentation differences to profound hearing loss with life-threatening Hirschsprung disease.
Whole genome sequencing evaluates all Waardenburg syndrome genes — PAX3, MITF, SOX10, EDNRB, EDN3, and SNAI2 — providing the subtype classification that determines whether Hirschsprung disease screening is indicated.
Waardenburg Syndrome
Waardenburg syndrome (WS) is a group of auditory-pigmentary syndromes caused by defects in neural crest cell migration and differentiation. Four clinical types are recognized: WS1 (PAX3 — sensorineural hearing loss, heterochromia iridis, white forelock, dystopia canthorum), WS2 (MITF, SOX10, SNAI2 — hearing loss and pigmentation without dystopia canthorum), WS3 (PAX3 — WS1 features plus limb anomalies, Waardenburg-Klein syndrome), and WS4 (SOX10, EDNRB, EDN3 — WS features plus Hirschsprung disease). WS accounts for approximately 2-5% of all congenital sensorineural hearing loss worldwide.
The pigmentary features — white forelock, premature graying, heterochromia iridis (different colored eyes), hypopigmented skin patches — are variable and may be absent or subtle. Many patients present with apparently isolated sensorineural hearing loss without obvious pigmentary changes, making Waardenburg syndrome easy to miss clinically. The key distinguishing feature in WS1/WS3 is dystopia canthorum (laterally displaced inner canthi), measured by the W-index. Hearing loss in WS is usually congenital, bilateral, and sensorineural, though unilateral and mild forms exist.
The critical clinical distinction between WS types is the association of WS4 with Hirschsprung disease — congenital absence of enteric ganglia causing functional intestinal obstruction. SOX10 pathogenic variants not only cause WS4 but can also cause peripheral demyelinating neuropathy (SOX10 is critical for Schwann cell and melanocyte development) and may be associated with progressive neurological deterioration. Identifying the specific WS gene determines the surveillance protocol: PAX3 patients need hearing management; SOX10/EDNRB/EDN3 patients need Hirschsprung screening and neurological monitoring.
SOX10 pathogenic variants cause WS4 with Hirschsprung disease risk and may also cause peripheral demyelinating neuropathy — features not seen with PAX3 or MITF variants. Subtype identification is management-critical.
Six genes cause Waardenburg syndrome. The specific gene determines whether the patient is at risk for Hirschsprung disease and peripheral neuropathy — information that hearing assessment alone does not provide.
SOX10 variants carry Hirschsprung disease risk — PAX3 and MITF variants do not
Hirschsprung disease — congenital intestinal aganglionosis requiring surgical intervention — occurs in Waardenburg syndrome type 4, caused by SOX10, EDNRB, or EDN3 pathogenic variants. It does not occur with PAX3 (WS1/WS3) or MITF (WS2) variants. An infant diagnosed with WS by clinical features or hearing loss evaluation who carries a SOX10 variant requires immediate Hirschsprung disease assessment — rectal suction biopsy, contrast enema — before presenting with life-threatening enterocolitis. Without molecular subtyping, this risk assessment cannot be accurately performed based on clinical features alone, since pigmentary and hearing features overlap between subtypes.
2-5% of congenital deafness is Waardenburg syndrome — molecular diagnosis changes recurrence counseling
For a family whose child has congenital hearing loss, the recurrence risk for subsequent children depends entirely on the underlying genetic cause. Connexin 26 (GJB2) hearing loss is autosomal recessive (25% recurrence). PAX3-related Waardenburg syndrome is autosomal dominant with variable expressivity — each subsequent child has a 50% chance of inheriting the variant, but the severity of hearing loss and pigmentary features is unpredictable. This distinction directly affects family planning decisions and prenatal management. Whole genome sequencing evaluates WS genes alongside GJB2 and other hearing loss genes, providing the comprehensive genetic diagnosis for accurate counseling.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Waardenburg Syndrome and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
